艾伯维公司 ABBV 深 沪
等待开盘 06-26 09:30:00 美东时间
242.145
+7.185
+3.06%
华盛通- 最 高243.25
- 今 开233.66
- 成交量 316.64万股
- 最 低 221.94
- 昨 收 234.96
- 总市值 4.28亿
- 52周最高 244.49
- 市盈率 静 37.52
- 换手率 179.20%
- 52周最低 184.63
- 委 比 18.18%
- 总股本 0.02亿
- 历史最高 244.49
- 量 比 1.13
- 振 幅 9.07%
- 历史最低 1.78
- 每 手 1
- 风险率 13.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.
06-24 01:11
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Monday. The Dow traded up 0.28% to 51,709.06 while the NASDAQ fell 1.31% to 26,170.77. The S&P 500 also
06-23 00:05
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
Reported Friday, 'AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics' - FT
https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1
06-22 16:24
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinutuzumab in chronic lymphocytic leukemia.
06-12 22:30
AbbVie, Oracle, Apple And More On CNBC's 'Final Trades'
Bryn Talkington picks AbbVie as final trade with $232 price target. Bill Baruch chooses Entegris . Oracle and Apple also feature.
06-05 20:26
AbbVie Exex Says Obseity Market Continues To Be Underpenetrated
-BofA Healthcare Conference
05-14 02:45
AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength
AbbVie Q1 2026 sales beat estimates as Skyrizi and Rinvoq drive growth, while Humira declines; company raises full-year EPS outlook.
04-30 02:49
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
The FDA flags manufacturing issues in AbbVie wrinkle drug filing; no safety concerns, response planned, $1.4 billion plant announced.
04-24 20:46
